Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1068526 | 0.92 | HDAC1 (0.68) | HDAC1HDAC2HDAC3NCOR2HPGD | |
| SCHEMBL1066670 | 0.91 | HDAC1 (0.67) | HDAC1HDAC2HDAC3NCOR2 | |
| SCHEMBL1063170 | 0.89 | HDAC1 (0.77) | HDAC1HDAC2HDAC3NCOR2 | |
| SCHEMBL1067964 | 0.89 | HDAC1 (0.72) | HDAC1HDAC2HDAC3NCOR2HPGD | |
| SCHEMBL8292244 | 0.86 | HDAC1 (0.77) | HDAC1HDAC2HDAC3NCOR2HPGD | |
| SCHEMBL1061676 | 0.86 | HDAC1 (0.56) | HDAC1HDAC2HPGD | |
| SCHEMBL1065638 | 0.84 | HDAC1 (0.66) | HDAC1HDAC2HDAC3 | |
| SCHEMBL1066696 | 0.84 | HDAC1 (0.76) | HDAC1HDAC2HDAC3NCOR2 | |
| SCHEMBL1067477 | 0.83 | HDAC1 (0.72) | HDAC1HDAC2HDAC3NCOR2HPGD | |
| SCHEMBL1067892 | 0.83 | HDAC1 (0.86) | HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868205-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7868205-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7868205-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| WO-2005030705-A9 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885HDAC2 5/4885HDAC3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.